IBDEI0I4 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8469,1,4,0)
 ;;=4^V17.7
 ;;^UTILITY(U,$J,358.3,8469,1,5,0)
 ;;=5^Family h/o Arthritis
 ;;^UTILITY(U,$J,358.3,8469,2)
 ;;=^295309
 ;;^UTILITY(U,$J,358.3,8470,0)
 ;;=V19.0^^35^485^5
 ;;^UTILITY(U,$J,358.3,8470,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8470,1,4,0)
 ;;=4^V19.0
 ;;^UTILITY(U,$J,358.3,8470,1,5,0)
 ;;=5^Family h/o Blindness
 ;;^UTILITY(U,$J,358.3,8470,2)
 ;;=^295320
 ;;^UTILITY(U,$J,358.3,8471,0)
 ;;=V16.3^^35^485^6
 ;;^UTILITY(U,$J,358.3,8471,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8471,1,4,0)
 ;;=4^V16.3
 ;;^UTILITY(U,$J,358.3,8471,1,5,0)
 ;;=5^Family h/o Cancer of Breast
 ;;^UTILITY(U,$J,358.3,8471,2)
 ;;=^295295
 ;;^UTILITY(U,$J,358.3,8472,0)
 ;;=V16.41^^35^485^9
 ;;^UTILITY(U,$J,358.3,8472,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8472,1,4,0)
 ;;=4^V16.41
 ;;^UTILITY(U,$J,358.3,8472,1,5,0)
 ;;=5^Family h/o Cancer of Ovary
 ;;^UTILITY(U,$J,358.3,8472,2)
 ;;=^317951
 ;;^UTILITY(U,$J,358.3,8473,0)
 ;;=V16.42^^35^485^10
 ;;^UTILITY(U,$J,358.3,8473,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8473,1,4,0)
 ;;=4^V16.42
 ;;^UTILITY(U,$J,358.3,8473,1,5,0)
 ;;=5^Family h/o Cancer of Prostate
 ;;^UTILITY(U,$J,358.3,8473,2)
 ;;=^317952
 ;;^UTILITY(U,$J,358.3,8474,0)
 ;;=V16.43^^35^485^11
 ;;^UTILITY(U,$J,358.3,8474,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8474,1,4,0)
 ;;=4^V16.43
 ;;^UTILITY(U,$J,358.3,8474,1,5,0)
 ;;=5^Family h/o Cancer of Testis
 ;;^UTILITY(U,$J,358.3,8474,2)
 ;;=^317953
 ;;^UTILITY(U,$J,358.3,8475,0)
 ;;=V19.5^^35^485^13
 ;;^UTILITY(U,$J,358.3,8475,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8475,1,4,0)
 ;;=4^V19.5
 ;;^UTILITY(U,$J,358.3,8475,1,5,0)
 ;;=5^Family h/o Congenital Anomalies
 ;;^UTILITY(U,$J,358.3,8475,2)
 ;;=^295325
 ;;^UTILITY(U,$J,358.3,8476,0)
 ;;=V19.2^^35^485^14
 ;;^UTILITY(U,$J,358.3,8476,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8476,1,4,0)
 ;;=4^V19.2
 ;;^UTILITY(U,$J,358.3,8476,1,5,0)
 ;;=5^Family h/o Deafness Or Hearing Loss
 ;;^UTILITY(U,$J,358.3,8476,2)
 ;;=^295322
 ;;^UTILITY(U,$J,358.3,8477,0)
 ;;=V17.3^^35^485^16
 ;;^UTILITY(U,$J,358.3,8477,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8477,1,4,0)
 ;;=4^V17.3
 ;;^UTILITY(U,$J,358.3,8477,1,5,0)
 ;;=5^Family h/o Ischemic Heart Dis
 ;;^UTILITY(U,$J,358.3,8477,2)
 ;;=^295305
 ;;^UTILITY(U,$J,358.3,8478,0)
 ;;=V16.6^^35^485^17
 ;;^UTILITY(U,$J,358.3,8478,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8478,1,4,0)
 ;;=4^V16.6
 ;;^UTILITY(U,$J,358.3,8478,1,5,0)
 ;;=5^Family h/o Leukemia
 ;;^UTILITY(U,$J,358.3,8478,2)
 ;;=^295298
 ;;^UTILITY(U,$J,358.3,8479,0)
 ;;=V18.61^^35^485^19
 ;;^UTILITY(U,$J,358.3,8479,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8479,1,4,0)
 ;;=4^V18.61
 ;;^UTILITY(U,$J,358.3,8479,1,5,0)
 ;;=5^Family h/o Polycystic Kidney
 ;;^UTILITY(U,$J,358.3,8479,2)
 ;;=^321531
 ;;^UTILITY(U,$J,358.3,8480,0)
 ;;=V17.0^^35^485^20
 ;;^UTILITY(U,$J,358.3,8480,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8480,1,4,0)
 ;;=4^V17.0
 ;;^UTILITY(U,$J,358.3,8480,1,5,0)
 ;;=5^Family h/o Psychiatric Condition
 ;;^UTILITY(U,$J,358.3,8480,2)
 ;;=^295302
 ;;^UTILITY(U,$J,358.3,8481,0)
 ;;=V19.4^^35^485^21
 ;;^UTILITY(U,$J,358.3,8481,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8481,1,4,0)
 ;;=4^V19.4
 ;;^UTILITY(U,$J,358.3,8481,1,5,0)
 ;;=5^Family h/o Skin Condition
 ;;^UTILITY(U,$J,358.3,8481,2)
 ;;=^295324
 ;;^UTILITY(U,$J,358.3,8482,0)
 ;;=V17.1^^35^485^22
 ;;^UTILITY(U,$J,358.3,8482,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8482,1,4,0)
 ;;=4^V17.1
 ;;^UTILITY(U,$J,358.3,8482,1,5,0)
 ;;=5^Family h/o Stroke (CVA)
 ;;^UTILITY(U,$J,358.3,8482,2)
 ;;=^295303
 ;;^UTILITY(U,$J,358.3,8483,0)
 ;;=V16.8^^35^485^12
 ;;
 ;;$END ROU IBDEI0I4
